Characteristics of recipients of cord blood or bone marrow from unrelated donors in 484 patients with acute myeloid leukemia and 336 patients with acute lymphoblastic leukemia
| Characteristic . | Acute myeloid leukemia . | Acute lymphoblastic leukemia . | ||||
|---|---|---|---|---|---|---|
| U-CBT . | U-BMT . | P . | U-CBT . | U-BMT . | P . | |
| No. of transplantations | 173 | 311 | 114 | 222 | ||
| Median patient age at transplantation, y (range) | 38 (16-69) | 38 (16-60) | .61 | 34 (16-58) | 32 (16-59) | .29 |
| Patient sex, n (%) | ||||||
| Male | 80 (46) | 194 (62) | < .001 | 52 (46) | 137 (62) | .005 |
| Female | 93 (54) | 117 (38) | 62 (54) | 85 (38) | ||
| Sex matching, n (%) | < .001 | .002 | ||||
| Matched | 83 (48) | 216 (69) | 52 (46) | 145 (65) | ||
| Male to female | 44 (25) | 57 (18) | 35 (31) | 42 (19) | ||
| Female to male | 46 (27) | 37 (12) | 27 (24) | 35 (16) | ||
| Unknown | 0 (0) | 1 (0) | 0 (0) | 0 (0) | ||
| Disease classification | ||||||
| AML (French-American-British) | .045 | |||||
| M0 | 17 (10) | 26 (8) | ||||
| M1 | 30 (17) | 38 (12) | ||||
| M2 | 52 (30) | 88 (28) | ||||
| M3 | 4 (2) | 25 (8) | ||||
| M4 | 27 (16) | 55 (18) | ||||
| M5 | 23 (13) | 41 (13) | ||||
| M6 | 3 (2) | 18 (6) | ||||
| M7 | 2 (1) | 5 (2) | ||||
| Others/unknown | 15 (9) | 15 (5) | ||||
| Cytogenetics | .042 | |||||
| Favorable* | 19 (11) | 66 (21) | ||||
| Normal | 74 (43) | 116 (37) | ||||
| Other | 57 (33) | 95 (31) | ||||
| Unknown | 23 (13) | 34 (11) | ||||
| ALL cytogenetics | .022 | |||||
| t(9;22) | 43 (38) | 52 (23) | ||||
| t(4;11) | 2 (2) | 3 (1) | ||||
| Others | 22 (19) | 51 (23) | ||||
| Normal | 27 (24) | 85 (38) | ||||
| Unknown | 20 (18) | 31 (14) | ||||
| Disease status | .003 | .33 | ||||
| First CR | 50 (29) | 130 (42) | 63 (55) | 130 (59) | ||
| Second or after CR | 39 (23) | 82 (26) | 21 (18) | 48 (22) | ||
| Relapse/induction failure | 81 (47) | 95 (31) | 30 (26) | 42 (19) | ||
| Unknown | 3 (2) | 4 (1) | 0 (0) | 2 (1) | ||
| HLA matching† | ||||||
| 0 mismatched loci | 12 (7) | 8 (7) | ||||
| 1 mismatched locus | 35 (20) | 25 (22) | ||||
| 2 mismatched loci | 126 (73) | 81 (71) | ||||
| ABO matching | < .001 | < .001 | ||||
| Matched | 59 (34) | 185 (59) | 37 (32) | 128 (58) | ||
| Minor mismatch | 48 (28) | 57 (18) | 30 (26) | 48 (22) | ||
| Major mismatch | 37 (21) | 59 (19) | 24 (21) | 41 (18) | ||
| Bidirectional | 28 (16) | 8 (3) | 23 (20) | 3 (1) | ||
| Unknown | 1 (1) | 2 (1) | 0 (0) | 2 (1) | ||
| Nucleated cells infused per 107/kg, median (range) | 2.44 (1.65-5.49) | 26.3 (2.10-58.8) | < .001 | 2.48 (1.51-4.06) | 28.2 (2.30-79.0) | < .001 |
| Preparative regimen | < .001 | .38 | ||||
| CY + TBI | 43 (25) | 142 (46) | 42 (37) | 92 (41) | ||
| CY + CA + TBI | 62 (36) | 41 (13) | 31 (27) | 53 (24) | ||
| CY + BU + TBI | 7 (4) | 36 (12) | 3 (3) | 5 (2) | ||
| Other TBI regimen | 42 (24) | 33 (11) | 34 (30) | 54 (24) | ||
| BU + CY | 18 (10) | 55 (18) | 4 (4) | 12 (5) | ||
| Other non-TBI regimen | 1 (1) | 4 (1) | 0 (0) | 6 (3) | ||
| GVHD prophylaxisis | < .001 | < .001 | ||||
| Cyclosporine A + sMTX | 103 (60) | 131 (42) | 65 (57) | 100 (45) | ||
| Cyclosporine A ± other | 20 (12) | 4 (1) | 6 (5) | 3 (1) | ||
| Tacrolimus + sMTX | 34 (20) | 168 (54) | 26 (23) | 106 (48) | ||
| Tacrolimus ± other | 15 (9) | 5 (2) | 16 (14) | 11 (5) | ||
| Others | 1 (1) | 3 (1) | 1 (1) | 2 (1) | ||
| Characteristic . | Acute myeloid leukemia . | Acute lymphoblastic leukemia . | ||||
|---|---|---|---|---|---|---|
| U-CBT . | U-BMT . | P . | U-CBT . | U-BMT . | P . | |
| No. of transplantations | 173 | 311 | 114 | 222 | ||
| Median patient age at transplantation, y (range) | 38 (16-69) | 38 (16-60) | .61 | 34 (16-58) | 32 (16-59) | .29 |
| Patient sex, n (%) | ||||||
| Male | 80 (46) | 194 (62) | < .001 | 52 (46) | 137 (62) | .005 |
| Female | 93 (54) | 117 (38) | 62 (54) | 85 (38) | ||
| Sex matching, n (%) | < .001 | .002 | ||||
| Matched | 83 (48) | 216 (69) | 52 (46) | 145 (65) | ||
| Male to female | 44 (25) | 57 (18) | 35 (31) | 42 (19) | ||
| Female to male | 46 (27) | 37 (12) | 27 (24) | 35 (16) | ||
| Unknown | 0 (0) | 1 (0) | 0 (0) | 0 (0) | ||
| Disease classification | ||||||
| AML (French-American-British) | .045 | |||||
| M0 | 17 (10) | 26 (8) | ||||
| M1 | 30 (17) | 38 (12) | ||||
| M2 | 52 (30) | 88 (28) | ||||
| M3 | 4 (2) | 25 (8) | ||||
| M4 | 27 (16) | 55 (18) | ||||
| M5 | 23 (13) | 41 (13) | ||||
| M6 | 3 (2) | 18 (6) | ||||
| M7 | 2 (1) | 5 (2) | ||||
| Others/unknown | 15 (9) | 15 (5) | ||||
| Cytogenetics | .042 | |||||
| Favorable* | 19 (11) | 66 (21) | ||||
| Normal | 74 (43) | 116 (37) | ||||
| Other | 57 (33) | 95 (31) | ||||
| Unknown | 23 (13) | 34 (11) | ||||
| ALL cytogenetics | .022 | |||||
| t(9;22) | 43 (38) | 52 (23) | ||||
| t(4;11) | 2 (2) | 3 (1) | ||||
| Others | 22 (19) | 51 (23) | ||||
| Normal | 27 (24) | 85 (38) | ||||
| Unknown | 20 (18) | 31 (14) | ||||
| Disease status | .003 | .33 | ||||
| First CR | 50 (29) | 130 (42) | 63 (55) | 130 (59) | ||
| Second or after CR | 39 (23) | 82 (26) | 21 (18) | 48 (22) | ||
| Relapse/induction failure | 81 (47) | 95 (31) | 30 (26) | 42 (19) | ||
| Unknown | 3 (2) | 4 (1) | 0 (0) | 2 (1) | ||
| HLA matching† | ||||||
| 0 mismatched loci | 12 (7) | 8 (7) | ||||
| 1 mismatched locus | 35 (20) | 25 (22) | ||||
| 2 mismatched loci | 126 (73) | 81 (71) | ||||
| ABO matching | < .001 | < .001 | ||||
| Matched | 59 (34) | 185 (59) | 37 (32) | 128 (58) | ||
| Minor mismatch | 48 (28) | 57 (18) | 30 (26) | 48 (22) | ||
| Major mismatch | 37 (21) | 59 (19) | 24 (21) | 41 (18) | ||
| Bidirectional | 28 (16) | 8 (3) | 23 (20) | 3 (1) | ||
| Unknown | 1 (1) | 2 (1) | 0 (0) | 2 (1) | ||
| Nucleated cells infused per 107/kg, median (range) | 2.44 (1.65-5.49) | 26.3 (2.10-58.8) | < .001 | 2.48 (1.51-4.06) | 28.2 (2.30-79.0) | < .001 |
| Preparative regimen | < .001 | .38 | ||||
| CY + TBI | 43 (25) | 142 (46) | 42 (37) | 92 (41) | ||
| CY + CA + TBI | 62 (36) | 41 (13) | 31 (27) | 53 (24) | ||
| CY + BU + TBI | 7 (4) | 36 (12) | 3 (3) | 5 (2) | ||
| Other TBI regimen | 42 (24) | 33 (11) | 34 (30) | 54 (24) | ||
| BU + CY | 18 (10) | 55 (18) | 4 (4) | 12 (5) | ||
| Other non-TBI regimen | 1 (1) | 4 (1) | 0 (0) | 6 (3) | ||
| GVHD prophylaxisis | < .001 | < .001 | ||||
| Cyclosporine A + sMTX | 103 (60) | 131 (42) | 65 (57) | 100 (45) | ||
| Cyclosporine A ± other | 20 (12) | 4 (1) | 6 (5) | 3 (1) | ||
| Tacrolimus + sMTX | 34 (20) | 168 (54) | 26 (23) | 106 (48) | ||
| Tacrolimus ± other | 15 (9) | 5 (2) | 16 (14) | 11 (5) | ||
| Others | 1 (1) | 3 (1) | 1 (1) | 2 (1) | ||
U-CBT, indicates unrelated cord blood transplantation; U-BMT, unrelated bone marrow transplantation; CR, complete remission; HLA, human leukocyte antigen; CY, cyclophosphamide; CA, cytarabine; BU, oral busulfan; TBI, total body irradiation; and sMTX, short-term methotrexate.
Favorable abnormal karyotypes are defined as t(8;21), inv16,or t(15;17).
Number of mismatches was counted among HLA-A, -B (low-resolution typing), and DRB1 (high-resolution typing).